8-K: Boston Scientific Subsidiary Prices and Completes €1.5 Billion Senior Notes Offering

American Medical Systems Europe B.V., a Boston Scientific subsidiary, successfully priced and completed a €1.5 billion offering of senior notes to refinance existing debt and for general corporate purposes.

Summary

• American Medical Systems Europe B.V. (AMS Europe), a wholly-owned finance subsidiary of Boston Scientific Corporation, priced a public offering of €850 million in 3.000% senior notes due 2031 and €650 million in 3.250% senior notes due 2034, totaling €1.5 billion.
• The notes are fully and unconditionally guaranteed by Boston Scientific Corporation.
• The offering was made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.
• The offering is expected to close on February 26, 2025, subject to customary closing conditions.
• The net proceeds from the offering, approximately €1.487 billion after deducting underwriting discounts and estimated expenses, will be used to repay AMS Europe's 0.750% senior notes due March 8, 2025, pay accrued interest, and for general corporate purposes.
• General corporate purposes may include short-term investments, reduction of short-term debt, funding of working capital, and potential future acquisitions.
• The notes are to be listed on the Official List of the Irish Stock Exchange plc trading as Euronext Dublin and to trading on the Global Exchange Market thereof.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The announcement is about a routine financial transaction (debt offering) to refinance existing debt and for general corporate purposes. The company is financially stable and the offering is expected to be completed successfully.

Positives

• The offering allows Boston Scientific to refinance existing debt at potentially favorable interest rates.
• The funds raised can be used for general corporate purposes, providing flexibility for investments, debt reduction, and acquisitions.
• The notes are listed on the Irish Stock Exchange, potentially increasing their visibility and liquidity.

Risks

• The press release contains forward-looking statements that are subject to various risks and uncertainties, which could cause actual results to differ materially from expectations.
• These risks include economic conditions, market competition, regulatory conditions, and other factors that are difficult to predict and beyond the company's control.

Future Outlook

The company intends to use the net proceeds from the offering, together with cash on hand, to fund the repayment at maturity of AMS Europe's 0.750% senior notes due March 8, 2025 and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.

Industry Context

This announcement reflects a common practice in the medical device industry, where companies routinely manage their debt profiles to optimize capital structure and fund strategic initiatives.

Comparison to Industry Standards

• Comparable companies such as Medtronic and Abbott often issue debt to finance acquisitions, research and development, or to refinance existing obligations.
• The interest rates and maturities of the notes are within the typical range for investment-grade corporate debt in the current market environment.
• For example, in 2024 Medtronic issued senior notes with maturities ranging from 3 to 30 years, with interest rates varying based on the term and prevailing market conditions.

Stakeholder Impact

• Shareholders may benefit from the optimized capital structure and strategic use of funds.
• Employees are unlikely to be directly impacted by this transaction.
• Customers and suppliers should not be directly affected by this financial maneuver.
• Creditors will see a change in the company's debt profile, with the issuance of new senior notes and the repayment of existing ones.

Next Steps

• The offering is expected to close on February 26, 2025, subject to customary closing conditions.
• Application has been made for the Notes to be admitted to the Official List of the Irish Stock Exchange plc trading as Euronext Dublin and to trading on the Global Exchange Market thereof.

Key Dates